Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1982 Jul;48(1):19–26. doi: 10.1136/hrt.48.1.19

Haemodynamic effects of nifedipine and propranolol in patients with hypertrophic obstructive cardiomyopathy.

K Landmark, S Sire, E Thaulow, J P Amlie, S Nitter-Hauge
PMCID: PMC481196  PMID: 7200796

Abstract

The haemodynamic effects of nifedipine, propranolol, and the combined administration of the two drugs were studied in 12 patients with hypertrophic obstructive cardiomyopathy. The combined administration of nifedipine and propranolol appeared to be superior to that of nifedipine alone. The spontaneous heart rate was reduced in most cases after nifedipine plus propranolol, and at atrial pacing the following results were obtained: left ventricular peak systolic pressure was reduced from 200 +/- 39 to 157 +/- 30 mmHg; a positive correlation was found between the pre-drug left ventricular end-diastolic pressure and the magnitude of reduction in left ventricular end-diastolic pressure; systolic blood pressure was reduced from 125 +/- 31 to 111 +/- 27 mmHg, and total peripheral resistance was reduced from 1403 +/- 307 to 1160 +/- 209 dyne s-1 cm-5. The combined administration reduced the resting left ventricular outflow gradient from 76 +/- 19 to 45 +/- 26 mmHg, while cardiac index was left unchanged. The effects on mean pulmonary arteriolar resistance and mean pulmonary arteriolar resistance and mean pulmonary capillary venous pressure were in most cases slight and insignificant. The results indicate an improved haemodynamic condition in patients with hypertrophic obstructive cardiomyopathy after the combined administration of nifedipine and propranolol: a treatment that might provide a new and useful alternative to already existing medication.

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman A. G., Shah P. M., Gramiak R., Wigle E. D. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J. 1970 Nov;32(6):804–811. doi: 10.1136/hrt.32.6.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Amlie J. P., Landmark K. The effect of nifedipine on the sinus and atrioventricular node of the dog heart after beta-adrenergic receptor blockade. Acta Pharmacol Toxicol (Copenh) 1978 Apr;42(4):287–291. doi: 10.1111/j.1600-0773.1978.tb02203.x. [DOI] [PubMed] [Google Scholar]
  3. Amsterdam E. A., Hughes J. L., DeMaria A. N., Zelis R., Mason D. T. Indirect assessment of myocardial oxygen consumption in the evaluation of mechanisms and therapy of angina pectoris. Am J Cardiol. 1974 May 20;33(6):737–743. doi: 10.1016/0002-9149(74)90214-8. [DOI] [PubMed] [Google Scholar]
  4. Atterhög J. H., Ekelund L. G. Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men. Eur J Clin Pharmacol. 1975 Jun 13;8(5):317–322. doi: 10.1007/BF00562656. [DOI] [PubMed] [Google Scholar]
  5. Beeler G. W., Jr, Reuter H. Membrane calcium current in ventricular myocardial fibres. J Physiol. 1970 Mar;207(1):191–209. doi: 10.1113/jphysiol.1970.sp009056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohen L. S., Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967 May;35(5):847–851. doi: 10.1161/01.cir.35.5.847. [DOI] [PubMed] [Google Scholar]
  7. Edwards R. H., Kristinsson A., Warrell D. A., Goodwin J. F. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br Heart J. 1970 Mar;32(2):219–225. doi: 10.1136/hrt.32.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ekelund L. G., Orö L. Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study. Clin Cardiol. 1979 Jun;2(3):203–211. doi: 10.1002/clc.4960020306. [DOI] [PubMed] [Google Scholar]
  9. Epstein S. E., Rosing D. R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981 Sep;64(3):437–441. doi: 10.1161/01.cir.64.3.437. [DOI] [PubMed] [Google Scholar]
  10. Flamm M. D., Harrison D. C., Hancock E. W. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation. 1968 Nov;38(5):846–858. doi: 10.1161/01.cir.38.5.846. [DOI] [PubMed] [Google Scholar]
  11. Goodwin J. F. Hypertrophic cardiomyopathy: a disease in search of its own identity. Am J Cardiol. 1980 Jan;45(1):177–180. doi: 10.1016/0002-9149(80)90236-2. [DOI] [PubMed] [Google Scholar]
  12. Goodwin J. F., Krikler D. M. Arrhythmia as a cause of sudden death in hypertrophic cardiomyopathy. Lancet. 1976 Oct 30;2(7992):937–940. doi: 10.1016/s0140-6736(76)90896-5. [DOI] [PubMed] [Google Scholar]
  13. Goodwin J. F., Oakley C. M. The cardiomyopathies. Br Heart J. 1972 Jun;34(6):545–552. doi: 10.1136/hrt.34.6.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Guazzi M., Olivari M. T., Polese A., Fiorentini C., Magrini F., Moruzzi P. Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):528–532. doi: 10.1002/cpt1977225part1528. [DOI] [PubMed] [Google Scholar]
  15. HARRISON D. C., BRAUNWALD E., GLICK G., MASON D. T., CHIDSEY C. A., ROSS J., Jr EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS. Circulation. 1964 Jan;29:84–98. doi: 10.1161/01.cir.29.1.84. [DOI] [PubMed] [Google Scholar]
  16. Hanrath P., Mathey D. G., Siegert R., Bleifeld W. Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: an echocardiographic study. Am J Cardiol. 1980 Jan;45(1):15–23. doi: 10.1016/0002-9149(80)90214-3. [DOI] [PubMed] [Google Scholar]
  17. Hardarson T., De la Calzada C. S., Curiel R., Goodwin J. F. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet. 1973 Dec 29;2(7844):1462–1467. doi: 10.1016/s0140-6736(73)92730-x. [DOI] [PubMed] [Google Scholar]
  18. Hashimoto K., Taira N., Chiba S., Hashimoto K., Jr, Endo M. Cardiohemodynamic effects of BAY a 1040 in the dog. Arzneimittelforschung. 1972 Jan;22(1):15–21. [PubMed] [Google Scholar]
  19. Henry P. D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980 Dec 1;46(6):1047–1058. doi: 10.1016/0002-9149(80)90366-5. [DOI] [PubMed] [Google Scholar]
  20. Hubner P. J., Ziady G. M., Lane G. K., Hardarson T., Scales B., Oakley C. M., Goodwin J. F. Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy. Br Heart J. 1973 Nov;35(11):1116–1123. doi: 10.1136/hrt.35.11.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. KRASNOW N., ROLETT E. L., YURCHAK P. M., HOOD W. B., Jr, GORLIN R. ISOPROTERENOL AND CARDIOVASCULAR PERFORMANCE. Am J Med. 1964 Oct;37:514–525. doi: 10.1016/0002-9343(64)90065-8. [DOI] [PubMed] [Google Scholar]
  22. Kaltenbach M., Hopf R., Kober G., Bussmann W. D., Keller M., Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979 Jul;42(1):35–42. doi: 10.1136/hrt.42.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Katz A. M., Repke D. I. Calcium-membrane interactions in the myocardium: effects of ouabain, epinephrine and 3',5'-cyclic adenosine monophosphate. Am J Cardiol. 1973 Feb;31(2):193–201. doi: 10.1016/0002-9149(73)91032-1. [DOI] [PubMed] [Google Scholar]
  24. Krikler D. Verapamil in cardiology. Eur J Cardiol. 1974 Aug;2(1):3–10. [PubMed] [Google Scholar]
  25. Landmark K., Amlie J. P. A study of the verapamil-induced changes in conductivity and refractoriness and monophasic action potentials of the dog heart in situ. Eur J Cardiol. 1976 Dec;4(4):419–427. [PubMed] [Google Scholar]
  26. Lorell B. H., Paulus W. J., Grossman W., Wynne J., Cohn P. F., Braunwald E. Improved diastolic function and systolic performance in hypertrophic cardiomyopathy after nifedipine. N Engl J Med. 1980 Oct 2;303(14):801–803. doi: 10.1056/NEJM198010023031407. [DOI] [PubMed] [Google Scholar]
  27. McKenna W. J., Chetty S., Oakley C. M., Goodwin J. F. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol. 1980 Jan;45(1):1–5. doi: 10.1016/0002-9149(80)90212-x. [DOI] [PubMed] [Google Scholar]
  28. Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
  29. Pedersen O. L., Mikkelsen E. Acute and chronic effects of nifedipine in arterial hypertension. Eur J Clin Pharmacol. 1978 Dec 18;14(6):375–381. doi: 10.1007/BF00716377. [DOI] [PubMed] [Google Scholar]
  30. Pedersen O. L., Mikkelsen E., Christensen N. J., Kornerup H. J., Pedersen E. B. Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension. Eur J Clin Pharmacol. 1979 May 21;15(4):235–240. doi: 10.1007/BF00618511. [DOI] [PubMed] [Google Scholar]
  31. Refsum H. Calcium-antagonistic and anti-arrhythmic effects of nifedipine on the isolated rat atrium. Acta Pharmacol Toxicol (Copenh) 1975 Nov;37(5):377–386. doi: 10.1111/j.1600-0773.1975.tb00856.x. [DOI] [PubMed] [Google Scholar]
  32. Rosing D. R., Kent K. M., Borer J. S., Seides S. F., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979 Dec;60(6):1201–1207. doi: 10.1161/01.cir.60.6.1201. [DOI] [PubMed] [Google Scholar]
  33. Rosing D. R., Kent K. M., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979 Dec;60(6):1208–1213. doi: 10.1161/01.cir.60.6.1208. [DOI] [PubMed] [Google Scholar]
  34. Rowland E., Evans T., Krikler D. Effect of nifedipine on atrioventricular conduction as compared with verapamil. Intracardiac electrophysiological study. Br Heart J. 1979 Aug;42(2):124–127. doi: 10.1136/hrt.42.2.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Shinebourne E. A., Hess M. L., White R. J., Hamer J. The effect of noradrenaline on the calcium uptake of the sarcoplasmic reticulum. Cardiovasc Res. 1969 Apr;3(2):113–117. doi: 10.1093/cvr/3.2.113. [DOI] [PubMed] [Google Scholar]
  36. Swan D. A., Bell B., Oakley C. M., Goodwin J. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J. 1971 Sep;33(5):671–685. doi: 10.1136/hrt.33.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. WIGLE E. D., DAVID P. R., LABROOSE C. J., MCMEEKAN J. MUSCULAR SUBAORTIC STENOSIS; THE INTERRELATION OF WALL TENSION, OUTFLOW TRACT "DISTENDING PRESSURE" AND ORIFICE RADIUS. Am J Cardiol. 1965 Jun;15:761–772. doi: 10.1016/0002-9149(65)90378-4. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES